Clinical trial
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
NCT00091715 · Actelion, Industry · Completed
Key facts
| NCT number | NCT00091715 |
|---|---|
| Title | Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II |
| Official title | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension (PAH) |
| Lead sponsor | Actelion, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Hypertension |
| Intervention type | Drug |
| Interventions | bosentan, placebo |
| Enrollment | 185 |
| Start date | Apr 1, 2004 |
| Primary completion | Nov 1, 2006 |
| Completion | Feb 1, 2011 |
| First posted | Sep 20, 2004 |
| Last update posted | Aug 30, 2011 |
| Countries | Australia, Austria, Belgium, Canada, China, Czechia, France, Germany, Italy, Netherlands, Spain, Switzerland and 2 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: